We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Evotec Logo

Evotec

Evotec are a R&D biotech that offers accelerating, high value pipeline co-creation partnerships and comprehensive CRO/CDMO services – always striving for highest quality, capital efficient execution of R&D programs from disease understanding towards IND, Phase 1, and beyond. Our expertise spans across therapeutic/disease areas and most modalities, especially small molecules and biotherapeutics. We take pride in acting as "drug hunters" in deep collaboration with our partners to advance science. At the core of our operations are our industrialized, AI-powered proprietary R&D platforms, including PanOmics and iPSC technologies. These platforms are instrumental in enhancing disease understanding and ensuring human relevance in our research. By integrating AI and continuous manufacturing technology, we facilitate better access to high-quality biotherapeutics, revolutionizing the way treatments are developed and produced.

Latest Evotec Content

Cells.
Product News

Evotec and Bristol Myers Squibb Expand Proteomics Partnership

Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced progress within the Company’s strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline.
Evotec Webinar - 4th December 2024
Webinar

High-Sensitivity Proteomics: The Next Frontier for Spatial and Single-Cell Biology

Improved sensitivity in proteomics analysis has numerous benefits including bringing down the sample requirements for analysis and thus facilitates a wide range of applications in drug discovery that were previously not feasible before.
Cell therapy.
Product News

Evotec and Novo Nordisk Enter Into Technology Development Partnership To Support Next-Generation Cell Therapies

Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies.
A bright blue vial and a DNA helix on a dark blue background, with the evotec logo in the corner.
Webinar

Harnessing microRNAs To Direct Bone and Cartilage Repair

On-Demand
Tissue engineering using stem cells represents a promising approach to repair bone damage caused by aging and trauma. However, the exact mechanisms behind the differentiation of skeletal stem cells have remained elusive.
evotec webinar 18th september
Webinar

Unlocking the Potential of miRNA-Targeted Therapies

On-Demand
In this webinar, our expert speaker will explore the therapeutic potential of miRNA- targeting treatments, outlining cutting-edge research that is identifying new miRNA targets.
A scientist wearing a lab coat works in a lab with a microscope.
Listicle

How AI and Machine Learning Can Improve Scientific Data Handling

Scientific researchers are discovering all kinds of applications for artificial intelligence and machine learning (AI/ML). This listicle will explore how AI/ML is being used in scientific research to accelerate discoveries and improve efficiency.

A 3D model of a human brain with coloured string emitting from the sides.
Product News

Evotec Announces Progress in Strategic Neuroscience Partnership With Bristol Myers Squibb

Key scientific achievement advances the joint neuroscience pipeline and earns a payment of US$ 25 m to Evotec to progress further research.
A single floating cell on a blue background.
Article

The Omics Revolution: Multiomics and the Future of Biomedical Research

Combining different types of omics data offers tantalizing opportunities to gain a more comprehensive overview of cellular systems. This article will explore some of the latest advances in multiomics analysis that have opened up new frontiers in cell biology.
A machine with multiple tubes for mass spectrometry proteomics in Drug Discovery
Product
Advertisement

Evotec’s ScreenPep™ : the new benchmark in high-throughput proteomics

Our ScreenPep™ platform sets a new benchmark in high-throughput proteomics, enabling the analysis of thousands of samples at unparalleled speed and depth. Combining high-end mass spectrometry with automated sample preparation to achieve exceptional coverage and precision.
3d illustration of proteins
Whitepaper

Mass Spectrometry-Based Solutions for Drugging the Undruggable

This whitepaper highlights new drug discovery platforms that can uncover and pharmacologically target previously undruggable proteins targets, making them accessible to therapeutic intervention by small-molecule drugs.
Advertisement